Lineage Cell Therapeutics, Inc.

LCTX · NYSE · SIC 2836: Biological Products, (No Diagnostic Substances)
473
SEC Filings

Business Summary

, Part I, Item 1A. Risk Factors, and Part II, Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations, but are also contained elsewhere in this report. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can iden...

Next Earnings

Q2 FY2026 — expected 2026-08-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLCTXdiscussed_in_filing Cybersecurity
topic_mentionLCTXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001193125-26-093992EDGAR108K words
2025-03-102024-12-310000950170-25-036309EDGAR—
2024-03-072023-12-310000950170-24-027988EDGAR—
2023-03-092022-12-310001493152-23-007129EDGAR—
2022-03-102021-12-310001493152-22-006520EDGAR—
2021-03-112020-12-310001493152-21-005814EDGAR—
2020-03-122019-12-310001493152-20-003818EDGAR—
2019-03-142018-12-310001493152-19-003335EDGAR—
2018-03-152017-12-310001493152-18-003416EDGAR—
2017-03-162016-12-310001140361-17-012402EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269599EDGAR30K words
2025-08-122025-06-300000950170-25-107333EDGAR—
2025-05-132025-03-310000950170-25-070378EDGAR—
2024-11-142024-09-300000950170-24-127077EDGAR—
2024-08-082024-06-300000950170-24-094004EDGAR—
2024-05-092024-03-310000950170-24-056998EDGAR—
2023-11-092023-09-300001493152-23-040058EDGAR—
2023-08-102023-06-300001493152-23-027552EDGAR—
2023-05-112023-03-310001493152-23-016392EDGAR—
2022-11-102022-09-300001493152-22-031359EDGAR—
2022-08-112022-06-300001493152-22-022085EDGAR—
2022-05-122022-03-310001493152-22-013041EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-110001193125-26-101167EDGAR1K words
2026-03-050001193125-26-093948EDGAR—
2025-11-280001193125-25-302552EDGAR—
2025-11-240001193125-25-291979EDGAR—
2025-11-120001193125-25-276249EDGAR—
2025-11-060001193125-25-269534EDGAR—
2025-08-260000950170-25-111319EDGAR—
2025-08-120000950170-25-107314EDGAR—
2025-07-020000950170-25-093007EDGAR—
2025-06-230000950170-25-088738EDGAR—

473 total filings indexed. 441 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0000876343
TickerLCTX
ExchangeNYSE
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedCA

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 5c5e4361f59e6ebe5b935f864dd8617570626c058380bd8cde9ed7473c909ffd
parent: 14933cc5d40bdf1f13cd0660ded3718bc414864a297e13928d3215150170b5d6
content hash: 4e388ca6cdd52e370974b18031973946fe50fb4336972968c803eb1f65d3ced8
signed: 2026-04-13T04:45:59.520Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf